Literature DB >> 25070615

[Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)].

T Zeus1, S Nitschmann, M Kelm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25070615     DOI： 10.1007/s00108-014-3559-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  4 in total

1.  Dabigatran and mechanical heart valves--not as easy as we hoped.

Authors:  Elaine M Hylek
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

3.  In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.

Authors:  Lars Maegdefessel; Torsten Linde; Franziska Krapiec; Kathrin Hamilton; Ulrich Steinseifer; Joanne van Ryn; Uwe Raaz; Michael Buerke; Karl Werdan; Axel Schlitt
Journal:  Thromb Res       Date:  2010-07-24       Impact factor: 3.944

Review 4.  Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends.

Authors:  Jack C J Sun; Michael J Davidson; Andre Lamy; John W Eikelboom
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.